Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial

Clin Oncol (R Coll Radiol). 2008 Jun;20(5):321-4. doi: 10.1016/j.clon.2008.02.010. Epub 2008 Apr 2.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Aromatase Inhibitors / administration & dosage*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Breast Neoplasms / prevention & control
  • Breast Neoplasms / therapy*
  • Clinical Trials as Topic
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Estrogen Antagonists / administration & dosage*
  • Estrogen Antagonists / pharmacology
  • Female
  • Fulvestrant
  • Humans
  • Neoplasm Recurrence, Local / prevention & control*
  • Receptors, Estrogen / antagonists & inhibitors

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Estrogen Antagonists
  • Receptors, Estrogen
  • Fulvestrant
  • Estradiol